lorazepam has been researched along with methadone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cerri, C; Cocco, E; Rovati, L | 1 |
| Deshpande, JK; Gregory, DF; Tobias, JD | 1 |
| Reid, C | 1 |
| da Silva, PS; Passos, RM; Waisberg, DR | 1 |
| Amirnovin, R; Koh, JY; Lieu, P; Nelson, LP; Okuhara, C; Rodgers, JW; Sanchez-Pinto, LN | 1 |
| Coulter, C; Garnier, M; Moore, C | 1 |
2 review(s) available for lorazepam and methadone
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for lorazepam and methadone
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Propranolol and clonidine in detoxification.
Topics: Clonidine; Humans; Lorazepam; Methadone; Opioid-Related Disorders; Propranolol; Psychomotor Agitation | 1988 |
Outpatient therapy of iatrogenic drug dependency following prolonged sedation in the pediatric intensive care unit.
Topics: Child; Female; Fentanyl; Humans; Iatrogenic Disease; Infant; Lorazepam; Male; Methadone; Midazolam; Phenobarbital; Substance Withdrawal Syndrome; Substance-Related Disorders | 1994 |
Medicating "Margaret".
Topics: Advance Directives; Alzheimer Disease; Analgesics, Opioid; Antipsychotic Agents; Electroconvulsive Therapy; Female; Fentanyl; Hospice Care; Humans; Lorazepam; Methadone; Middle Aged; Morphine; Oxycodone; Pain; Palliative Care; Psychomotor Agitation; Right to Die | 2006 |
Withdrawal treatment with clonidine after prolonged use of chloral hydrate in a pediatric intensive care patient.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Chloral Hydrate; Clonidine; Fentanyl; Humans; Hypnotics and Sedatives; Infant; Intensive Care, Neonatal; Lorazepam; Male; Methadone; Midazolam; Pneumonia; Respiratory Insufficiency; Substance Withdrawal Syndrome | 2011 |
Implementation of a Risk-Stratified Opioid and Benzodiazepine Weaning Protocol in a Pediatric Cardiac ICU.
Topics: Analgesics, Opioid; Benzodiazepines; Cardiovascular Diseases; Female; Humans; Hydromorphone; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Length of Stay; Lorazepam; Male; Methadone; Prospective Studies; Risk Assessment; Severity of Illness Index; Substance Withdrawal Syndrome | 2018 |
Rapid Extraction and Qualitative Screening of 30 Drugs in Oral Fluid at Concentrations Recommended for the Investigation of DUID Cases.
Topics: 2-Propanol; 3,4-Methylenedioxyamphetamine; Alprazolam; Amphetamines; Buprenorphine; Carisoprodol; Clonazepam; Cocaine; Codeine; Dronabinol; Fentanyl; Hexanes; Hydrocodone; Hydromorphone; Lorazepam; Meprobamate; Methadone; Methamphetamine; Morphine Derivatives; N-Methyl-3,4-methylenedioxyamphetamine; Nordazepam; Oxazepam; Oxycodone; Oxymorphone; Pharmaceutical Preparations; Phencyclidine; Tandem Mass Spectrometry; Temazepam; Tramadol; Zolpidem | 2022 |